Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma
In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 micrograms; in the se...
Gespeichert in:
| Veröffentlicht in: | Rheumatology international 1987-01, Vol.7 (3), p.127-132 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 132 |
|---|---|
| container_issue | 3 |
| container_start_page | 127 |
| container_title | Rheumatology international |
| container_volume | 7 |
| creator | Lemmel, E M Franke, M Gaus, W Hartl, P W Hofschneider, P H Miehlke, K Machalke, K Obert, H J |
| description | In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 micrograms; in the second, 100 micrograms. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. |
| doi_str_mv | 10.1007/BF00270465 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_81082243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81082243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-f3e909b262fdf56e10352d550978b0c96de58ddf0039803bae9cf000ea60b5da3</originalsourceid><addsrcrecordid>eNpFkE1LAzEURYMotVY37oVZuRBGX5L5XGqxWigIouBuyCQvNjqZqUkG8d-b0qKb-96Fw10cQs4pXFOA8uZuAcBKyIr8gExpxsuUFvB2SKZAS5ZWMY7JifcfEHtRwIRMOKVVlvEp-XxGP3bBJ4NORLJZC4_pcpnIzvRGii4JzsQc-vigCBb7sCXdGkcrwmBUIlxYOxOMT75NWCcO5WBb04sImj6g0-iGPn0X1opTcqRF5_Fsf2fkdXH_Mn9MV08Py_ntKpWsYiHVHGuoW1YwrXReIAWeM5XnUJdVC7IuFOaVUhqA1xXwVmAtYwEUBbS5EnxGLne7Gzd8jehDY42X2HWix2H0TUWhYizjEbzagdIN3jvUzcYZK9xPQ6HZmm3-zUb4Yr86thbVH7pXyX8Bi_p0YQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>81082243</pqid></control><display><type>article</type><title>Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Lemmel, E M ; Franke, M ; Gaus, W ; Hartl, P W ; Hofschneider, P H ; Miehlke, K ; Machalke, K ; Obert, H J</creator><creatorcontrib>Lemmel, E M ; Franke, M ; Gaus, W ; Hartl, P W ; Hofschneider, P H ; Miehlke, K ; Machalke, K ; Obert, H J</creatorcontrib><description>In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 micrograms; in the second, 100 micrograms. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed.</description><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/BF00270465</identifier><identifier>PMID: 3118443</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - therapeutic use ; Arthritis, Rheumatoid - physiopathology ; Arthritis, Rheumatoid - therapy ; Drug Evaluation ; Drug Therapy, Combination ; Female ; Humans ; Interferon-gamma - administration & dosage ; Interferon-gamma - adverse effects ; Interferon-gamma - therapeutic use ; Male ; Middle Aged ; Pain Management ; Recombinant Proteins</subject><ispartof>Rheumatology international, 1987-01, Vol.7 (3), p.127-132</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-f3e909b262fdf56e10352d550978b0c96de58ddf0039803bae9cf000ea60b5da3</citedby><cites>FETCH-LOGICAL-c282t-f3e909b262fdf56e10352d550978b0c96de58ddf0039803bae9cf000ea60b5da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3118443$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lemmel, E M</creatorcontrib><creatorcontrib>Franke, M</creatorcontrib><creatorcontrib>Gaus, W</creatorcontrib><creatorcontrib>Hartl, P W</creatorcontrib><creatorcontrib>Hofschneider, P H</creatorcontrib><creatorcontrib>Miehlke, K</creatorcontrib><creatorcontrib>Machalke, K</creatorcontrib><creatorcontrib>Obert, H J</creatorcontrib><title>Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><description>In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 micrograms; in the second, 100 micrograms. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - physiopathology</subject><subject>Arthritis, Rheumatoid - therapy</subject><subject>Drug Evaluation</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Interferon-gamma - administration & dosage</subject><subject>Interferon-gamma - adverse effects</subject><subject>Interferon-gamma - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pain Management</subject><subject>Recombinant Proteins</subject><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEURYMotVY37oVZuRBGX5L5XGqxWigIouBuyCQvNjqZqUkG8d-b0qKb-96Fw10cQs4pXFOA8uZuAcBKyIr8gExpxsuUFvB2SKZAS5ZWMY7JifcfEHtRwIRMOKVVlvEp-XxGP3bBJ4NORLJZC4_pcpnIzvRGii4JzsQc-vigCBb7sCXdGkcrwmBUIlxYOxOMT75NWCcO5WBb04sImj6g0-iGPn0X1opTcqRF5_Fsf2fkdXH_Mn9MV08Py_ntKpWsYiHVHGuoW1YwrXReIAWeM5XnUJdVC7IuFOaVUhqA1xXwVmAtYwEUBbS5EnxGLne7Gzd8jehDY42X2HWix2H0TUWhYizjEbzagdIN3jvUzcYZK9xPQ6HZmm3-zUb4Yr86thbVH7pXyX8Bi_p0YQ</recordid><startdate>19870101</startdate><enddate>19870101</enddate><creator>Lemmel, E M</creator><creator>Franke, M</creator><creator>Gaus, W</creator><creator>Hartl, P W</creator><creator>Hofschneider, P H</creator><creator>Miehlke, K</creator><creator>Machalke, K</creator><creator>Obert, H J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19870101</creationdate><title>Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma</title><author>Lemmel, E M ; Franke, M ; Gaus, W ; Hartl, P W ; Hofschneider, P H ; Miehlke, K ; Machalke, K ; Obert, H J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-f3e909b262fdf56e10352d550978b0c96de58ddf0039803bae9cf000ea60b5da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - physiopathology</topic><topic>Arthritis, Rheumatoid - therapy</topic><topic>Drug Evaluation</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Interferon-gamma - administration & dosage</topic><topic>Interferon-gamma - adverse effects</topic><topic>Interferon-gamma - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pain Management</topic><topic>Recombinant Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lemmel, E M</creatorcontrib><creatorcontrib>Franke, M</creatorcontrib><creatorcontrib>Gaus, W</creatorcontrib><creatorcontrib>Hartl, P W</creatorcontrib><creatorcontrib>Hofschneider, P H</creatorcontrib><creatorcontrib>Miehlke, K</creatorcontrib><creatorcontrib>Machalke, K</creatorcontrib><creatorcontrib>Obert, H J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lemmel, E M</au><au>Franke, M</au><au>Gaus, W</au><au>Hartl, P W</au><au>Hofschneider, P H</au><au>Miehlke, K</au><au>Machalke, K</au><au>Obert, H J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma</atitle><jtitle>Rheumatology international</jtitle><addtitle>Rheumatol Int</addtitle><date>1987-01-01</date><risdate>1987</risdate><volume>7</volume><issue>3</issue><spage>127</spage><epage>132</epage><pages>127-132</pages><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 micrograms; in the second, 100 micrograms. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed.</abstract><cop>Germany</cop><pmid>3118443</pmid><doi>10.1007/BF00270465</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0172-8172 |
| ispartof | Rheumatology international, 1987-01, Vol.7 (3), p.127-132 |
| issn | 0172-8172 1437-160X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_81082243 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - therapeutic use Arthritis, Rheumatoid - physiopathology Arthritis, Rheumatoid - therapy Drug Evaluation Drug Therapy, Combination Female Humans Interferon-gamma - administration & dosage Interferon-gamma - adverse effects Interferon-gamma - therapeutic use Male Middle Aged Pain Management Recombinant Proteins |
| title | Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T00%3A41%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20a%20phase-II%20clinical%20trial%20on%20treatment%20of%20rheumatoid%20arthritis%20with%20recombinant%20interferon-gamma&rft.jtitle=Rheumatology%20international&rft.au=Lemmel,%20E%20M&rft.date=1987-01-01&rft.volume=7&rft.issue=3&rft.spage=127&rft.epage=132&rft.pages=127-132&rft.issn=0172-8172&rft.eissn=1437-160X&rft_id=info:doi/10.1007/BF00270465&rft_dat=%3Cproquest_cross%3E81082243%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=81082243&rft_id=info:pmid/3118443&rfr_iscdi=true |